AI PLATFORM TECHNOLOGIES We strive to develop novel drugs with an unprecedented level of efficacy and precision. Using AI, we simulate the human immune system and generate predictive models to identify and develop personalized and other next-generation immunotherapies for patients.
ONCOLOGY
PIONEER is a proprietary AI platform for the rapid discovery of patient-specific neoantigens used for our personalized cancer immunotherapies. We want to challenge and improve the standardized therapies of today, where one size fits all, risking unspecific immune activation. With our AI technologies, we seek out and target cancer cells, creating truly personalized therapies where one size fits one and only one.
Related Resources
Jun 3, 2023
Press releases
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
May 25, 2023
Press releases
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
May 25, 2023
Press releases
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
Mar 27, 2023
Publications
Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.